Literature DB >> 24312841

Extractive spectrophotometric determination of ambrisentan.

Namasani Santhosh Kumar1, Avula Prameela Rani, Telu Visalakshi, Chandra Bala Sekharan.   

Abstract

PURPOSE: Ambrisentan (ABS) is an antihypertensive drug used in the treatment of pulmonary atrial hypertension. The survey of literature for ABS revealed only two spectrophotometric methods for its quantification. The reported methods lack the sensitivity. This study is aimed at developing two sensitive extractive spectrophotometric methods for the determination of ABS in bulk and in tablets.
METHODS: The proposed methods are based on the formation of colored chloroform extractable ion-pair complexes of ABS with methylene blue (MB method) and safranine O (SO method) in buffered solution at pH 9.8. The extracted complexes showed maximum absorbance at 525 and 515 nm for methylene blue and safranine O, respectively.
RESULTS: In both the methods, the calibration curve was linear from 1-15 µg mL(-1) of drug. Apparent molar absorpitivities were 1.7911 x 10(5), 2.3272 x 10(5) L mol(-1) cm(-1); Sandell's sensitivities were 0.0215, 0.0162 µg cm(-2); LOD were 0.182, 0.175 µg mL(-1); LOQ were 0.551, 0.531 µg mL(-1) for methods MB and SO, respectively. The relative standard deviation and percent recovery ranged from 0.206-1.310% and 99.0-101.5%, respectively.
CONCLUSION: The results demonstrate that the proposed methods are sensitive, precise, accurate and inexpensive. These methods can easily be used for the assay of ABS in quality control laboratories.

Entities:  

Keywords:  Ambrisentan; Ion-Pair complex; Methylene blue; Safranine O

Year:  2013        PMID: 24312841      PMCID: PMC3846032          DOI: 10.5681/apb.2013.038

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  10 in total

1.  Rapid determination of ambrisentan enantiomers by enantioselective liquid chromatography using cellulose-based chiral stationary phase in reverse phase mode.

Authors:  Michal Douša; Petr Gibala
Journal:  J Sep Sci       Date:  2012-04       Impact factor: 3.645

2.  Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.

Authors:  James R Klinger; Ronald J Oudiz; Rebecca Spence; Darrin Despain; Christopher Dufton
Journal:  Am J Cardiol       Date:  2011-05-03       Impact factor: 2.778

Review 3.  Ambrisentan, a non-peptide endothelin receptor antagonist.

Authors:  Hartmut Vatter; Volker Seifert
Journal:  Cardiovasc Drug Rev       Date:  2006

Review 4.  Ambrisentan.

Authors:  James E Frampton
Journal:  Am J Cardiovasc Drugs       Date:  2011-08-01       Impact factor: 3.571

5.  LC-ESI-MS/MS method for quantification of ambrisentan in plasma and application to rat pharmacokinetic study.

Authors:  Ramakrishna Nirogi; Vishwottam Kandikere; Prashanth Komarneni; Raghupathi Aleti; Nagasuryaprakash Padala; Ilayaraja Kalaikadhiban
Journal:  Biomed Chromatogr       Date:  2012-01-04       Impact factor: 1.902

6.  Extractive spectrophotometric determination of TRODAT-1 hydrochloride in lyophilized kit.

Authors:  X M Li; Z P Chen; S P Wang; J Tang; C Y Liu; M F Zou
Journal:  Pharmazie       Date:  2008-09       Impact factor: 1.267

7.  Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.

Authors:  Ronald J Oudiz; Nazzareno Galiè; Horst Olschewski; Fernando Torres; Adaani Frost; Hossein A Ghofrani; David B Badesch; Michael D McGoon; Vallerie V McLaughlin; Ellen B Roecker; Brooke C Harrison; Darrin Despain; Christopher Dufton; Lewis J Rubin
Journal:  J Am Coll Cardiol       Date:  2009-11-17       Impact factor: 24.094

8.  A new spectrophotometric method for the determination of tianeptine in tablets using ion-pair reagents.

Authors:  Sevgi Tatar Ulu; Zeynep Aydogmus
Journal:  Chem Pharm Bull (Tokyo)       Date:  2008-12       Impact factor: 1.645

9.  [Study on extractive spectrophotometry for determination of amoxicillin with ionic associate].

Authors:  Ya-li Duan; Li-ming Du; Cai-ping Chen
Journal:  Guang Pu Xue Yu Guang Pu Fen Xi       Date:  2005-11       Impact factor: 0.589

10.  Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

Authors:  Nazzareno Galiè; Horst Olschewski; Ronald J Oudiz; Fernando Torres; Adaani Frost; Hossein A Ghofrani; David B Badesch; Michael D McGoon; Vallerie V McLaughlin; Ellen B Roecker; Michael J Gerber; Christopher Dufton; Brian L Wiens; Lewis J Rubin
Journal:  Circulation       Date:  2008-05-27       Impact factor: 29.690

  10 in total
  1 in total

1.  Stability-Indicating RP-HPLC Method for the Determination of Ambrisentan and Tadalafil in Pharmaceutical Dosage Form.

Authors:  Jayvadan K Patel; Nilam K Patel
Journal:  Sci Pharm       Date:  2014-05-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.